SCHEMBL96079

SCHEMBL96079

[CH2]c1ccc(NC(=O)Oc2ccccc2OC)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.73
SMN1; SMN2 Q16637 5/20 0.50
ALDH1A1 P00352 3/20 0.50
HTT P42858 2/20 0.50
GAA P10253 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
POLB P06746 1/20 0.48
RAB9A P51151 3/20 0.47
FAAH O00519 3/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 3/20 0.46
TSHR P16473 1/20 0.46
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NPC1 O15118 1/20 0.46
KDM4E B2RXH2 1/20 0.46
BLM P54132 1/20 0.46
MTNR1B P49286 1/20 0.45
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31527768 0.87 ATM (0.77) ATMSMN1; SMN2ALDH1A1HTTGAA
SCHEMBL15942943 0.86 ATM (0.75) ATMSMN1; SMN2ALDH1A1HTTGAA
SCHEMBL7248115 0.84 ATM (0.56) ATMSMN1; SMN2ALDH1A1HTTGAA
SCHEMBL25488355 0.83 ATM (0.71) ATMSMN1; SMN2ALDH1A1HTTGAA
SCHEMBL15942942 0.82 ATM (0.69) ATMSMN1; SMN2ALDH1A1HTTGAA
SCHEMBL14679665 0.81 ATM (0.68) ATMSMN1; SMN2ALDH1A1HTTGAA
SCHEMBL13561035 0.79 ATM (0.65) ATMSMN1; SMN2ALDH1A1HTTPOLB
SCHEMBL94630 0.78 MAPT (0.69) SMN1; SMN2ALDH1A1POLBRAB9AKMT2A
SCHEMBL94538 0.78 SMN1; SMN2 (0.71) SMN1; SMN2ALDH1A1HTTGAAPOLB
SCHEMBL95445 0.77 SMN1; SMN2 (0.67) SMN1; SMN2ALDH1A1GAAPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB ATM 1126/4885SMN1; SMN2 3998/4885ALDH1A1 2948/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 ATM 723/4885SMN1; SMN2 3084/4885ALDH1A1 2458/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 ATM 723/4885SMN1; SMN2 3084/4885ALDH1A1 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.